Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immutep Ltd ADR
(NQ:
IMMP
)
2.360
-0.030 (-1.26%)
Streaming Delayed Price
Updated: 1:22 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
61,195
Open
2.400
Bid (Size)
2.360 (21)
Ask (Size)
2.370 (1)
Prev. Close
2.390
Today's Range
2.315 - 2.466
52wk Range
1.550 - 2.950
Shares Outstanding
748,152,935
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
March 05, 2024
Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall...
Via
Benzinga
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
October 24, 2023
From
Immutep Limited
Via
GlobeNewswire
Performance
YTD
+0.42%
+0.42%
1 Month
+4.42%
+4.42%
3 Month
-4.07%
-4.07%
6 Month
+22.91%
+22.91%
1 Year
+42.16%
+42.16%
More News
Read More
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
October 23, 2023
From
Immutep Limited
Via
GlobeNewswire
7 Stocks That Could Triple Your Money by 2024
August 09, 2023
Via
InvestorPlace
Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting
May 24, 2023
Via
Benzinga
Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know
May 18, 2023
Via
Benzinga
Immutep Issues Development Update For Its Lead Cancer Candidate
September 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
August 03, 2023
Via
Benzinga
3 Best Penny Stocks Under $3 to Buy in June
June 14, 2023
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 24, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 17, 2023
Via
Benzinga
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
May 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 17, 2023
Via
Benzinga
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 17, 2023
From
Immutep Limited
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
May 17, 2023
Via
InvestorPlace
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
May 01, 2023
From
Immutep Limited
Via
GlobeNewswire
7 Best Penny Stocks Under $3 to Buy in April
April 12, 2023
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
April 03, 2023
Via
InvestorPlace
Why Did Immutep Ltd Stock Soar Recently?
December 28, 2022
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
November 29, 2022
From
Immutep Limited
Via
GlobeNewswire
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
November 09, 2022
From
Immutep Limited
Via
GlobeNewswire
Why AeroClean Technologies Is Trading Higher By Over 39%; Here Are 26 Stocks Moving Premarket
October 04, 2022
Via
Benzinga
Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment
August 01, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 04, 2022
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.